Using XMD8-92, it was later shown that ERK5 inhibition blocks tumor cell proliferation in vitro and significantly inhibits tumor growth in vivo, demonstrating the efficacy and tolerability of ERK5 targeting for cancer treatment in preclinical models [68]. Here, MAPK7 is linked to cancer.